X-linked Hypophosphatemia Clinical Trial
Official title:
Examining the Effect of Burosumab on Muscle Function Using MR Spectroscopy
Verified date | August 2023 |
Source | Yale University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Patients with X-linked hypophosphatemia (XLH) often report symptoms of fatigue and weakness particularly after exertion, in addition to their skeletal complaints. In previous trials using KRN23 (same drug as burosumab/Crysvita®), patients report these symptoms improve. The investigators wish to test this hypothesis directly by measuring muscle energy when patients begin treatment with Crysvita® for the first time.
Status | Completed |
Enrollment | 10 |
Est. completion date | August 25, 2022 |
Est. primary completion date | August 25, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. 18-65 years of age 2. Diagnosis of XLH 3. eGFR = 50 (estimated glomerular filtration rate) 4. Normal serum calcium 5. Phosphate = 2.5 mg/dl 6. Deemed clinically appropriate for starting therapy with Burosumab/Crysvita® (based on the treating physician's evaluation) 7. Deemed appropriate for MR Spectroscopy Exclusion Criteria: 1. Patients with fixed skeletal abnormalities which would prevent them from successfully completing study-related functional assessments 2. Patients unwilling to stop therapy with supplemental phosphate and calcitriol 2 weeks prior to enrollment. 3. Patients who have undergone an orthopaedic procedure within the previous 6 months involving implantation of metal hardware |
Country | Name | City | State |
---|---|---|---|
United States | Yale University School of Medicine | New Haven | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Yale University |
United States,
Pesta DH, Tsirigotis DN, Befroy DE, Caballero D, Jurczak MJ, Rahimi Y, Cline GW, Dufour S, Birkenfeld AL, Rothman DL, Carpenter TO, Insogna K, Petersen KF, Bergwitz C, Shulman GI. Hypophosphatemia promotes lower rates of muscle ATP synthesis. FASEB J. 2016 Oct;30(10):3378-3387. doi: 10.1096/fj.201600473R. Epub 2016 Jun 23. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Six-minute Walk Test | functional testing outcome measured in meters | 2.5 months | |
Other | Sit to Stand | functional testing outcome measured in the number completed in 30 seconds | 2.5 months | |
Other | Timed up and go Test | functional testing outcome measured in seconds | 2.5 months | |
Primary | Skeletal Muscle Adenosine Triphosphate (ATP) Synthesis Rate | Rates of mitochondrial phosphorylation activity were assessed in the soleus/gastrocnemius muscle complex of the right calf by 31P magnetic resonance spectroscopy saturation transfer technique (micro-mol/g/min) | 2.5 months | |
Secondary | Serum Phosphate | measured in mg/dl | 2.5 months | |
Secondary | Intracellular Phosphate Concentration in Umol/g Muscle | Intracellular phosphorus concentration in skeletal muscle (umol/g muscle) | 2.5 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915705 -
Efficacy and Safety of Burosumab (KRN23) Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)
|
Phase 3 | |
Recruiting |
NCT03879915 -
Dental Implants in Patients With X-linked Hypophosphatemia
|
||
Active, not recruiting |
NCT03193476 -
Registry for Patients With X-Linked Hypophosphatemia
|
||
Completed |
NCT02526160 -
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
|
Phase 3 | |
Completed |
NCT05181839 -
A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth
|
||
Completed |
NCT02750618 -
Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)
|
Phase 2 | |
Active, not recruiting |
NCT03745521 -
Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian Partners
|
||
Completed |
NCT03920072 -
Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH
|
Phase 3 | |
Recruiting |
NCT03748966 -
Calcitriol Monotherapy for X-Linked Hypophosphatemia
|
Early Phase 1 | |
Recruiting |
NCT04419363 -
Burosumab in Children and Adolescents With X-linked Hypophosphatemia
|
Phase 4 | |
Completed |
NCT02163577 -
Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)
|
Phase 2 | |
Active, not recruiting |
NCT03651505 -
X-linked Hypophosphatemia Disease Monitoring Program
|
||
Completed |
NCT06067932 -
Foot Disorders in X-linked Hypophosphatemia
|
||
Completed |
NCT04695860 -
Anti-FGF23 (Burosumab) in Adult Patients With XLH
|
Phase 3 | |
Completed |
NCT02312687 -
Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
|
Phase 2 | |
Completed |
NCT03596554 -
X-linked Hypophosphatemia and FGF21
|
||
Recruiting |
NCT03820518 -
Using Different Doses of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosphatemia
|
Phase 4 | |
Completed |
NCT01571596 -
An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
|
Phase 1/Phase 2 | |
Completed |
NCT04273490 -
Characterising Pain, QoL, Body Composition, Arterial Stiffness, Muscles and Bones in Adult Persons With XLH and Healthy Controls
|
||
Completed |
NCT03489993 -
FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP)
|